Table 3 Treatment response after 1-year Tafamidis treatment
|  | Pre Tafamidis (N = 14) | 12 m Tafamidis (N = 14) | P value |
|---|---|---|---|
Functional status | |||
 NYHA Fc I | 1 (7%) | 3 (21%) | 0.083 |
 NYHA Fc II | 12 (86%) | 11 (79%) | |
 NYHA Fc II | 1 (7%) | 0 | |
Improved: 3 (21%) Stationary: 11 (79%) Worse: 0 (0%) | |||
Biochemistry | |||
 Creatinine, mg/dL | 0.76 ± 0.21 | 0.70 ± 0.17 | 0.024 |
 Triglyceride, mg/dL | 74.5 ± 27.0 | 76.6 ± 38.8 | 0.859 |
 Total cholesterol, mg/dL | 173.9 ± 31.6 | 176.0 ± 37.8 | 0.610 |
 Fasting blood glucose, mg/dL | 83.5 ± 15.0 | 88.9 ± 23.9 | 0.834 |
 Albumin, g/dL | 4.1 ± 0.2 | 7.9 ± 12.3 | 0.833 |
 Prealbumin*, mg/dL | 27.1 ± 9.1 | 32.0 ± 7.7 | 0.046 |
 Log NT-ProBNP | 3.0 ± 0.54 | 2.9 ± 0.47 | 0.272 |
 NT-ProBNP, pg/mL | 2078.1 ± 3886.3 | 1133.4 ± 1032.6 | 0.221 |
Echocardiography | Â | ||
 IVSD, mm | 15.4 ± 2.5 | 15.4 ± 2.8 | 1.000 |
 LVPWD, mm | 14.8 ± 2.1 | 14.2 ± 2.5 | 0.119 |
 LVEDD, mm | 45.2 ± 3.7 | 45.0 ± 4.5 | 0.936 |
 LVESD, mm | 31.6 ± 4.8 | 30.9 ± 6.7 | 0.550 |
 LVEF, % | 56.6 ± 11.7 | 58.8 ± 15.1 | 0.594 |
 LA diameter, mm | 40.5 ± 4.5 | 40.5 ± 6.1 | 0.906 |
Cardiac MRI | |||
 LVEF, % | 54.1 ± 9.5 | 53.1 ± 12.5 | 0.683 |
 LVEDVi, ml/m2 | 69.3 ± 16.7 | 76.2 ± 22.3 | 0.177 |
 LVESVi, ml/m2 | 32.3 ± 12.0 | 36.4 ± 15.4 | 0.551 |
 LVMi, g/m2 | 93.0 ± 24.8 | 97.7 ± 31.2 | 0.331 |
 GRS, % | 19.2 ± 8.9 | 18.8 ± 9.0 | 0.433 |
 GCS, % | -12.6 ± 4.3 | -12.3 ± 4.5 | 0.363 |
 GLS, % | -8.7 ± 3.3 | -8.9 ± 3.5 | 0.730 |
 Native T1 Mapping, ms | 1159.5 ± 53.0 | 1157.4 ± 68.2 | 0.975 |
 ECV, % | 51.5 ± 8.9 | 49.0 ± 9.4 | 0.041 |